Pasireotide for Malignant Insulinoma

Overview

Journal Hormones (Athens)

Specialty Endocrinology

Date 2016 Jan 7

PMID 26732164

Citations 21

Authors

Amit Tirosh

Salomon M Stemmer

Evgeny Solomonov

Eldad Elnekave

Wolfgang Saeger

Yelena Ravkin

Kobi Nir

Yeela Talmor

Ilan Shimon

Affiliations

Soon will be listed here.

Abstract

Unlabelled: Malignant insulinoma usually has a poor prognosis, as no efficient medical treatment is available. The somatostatin analogs octreotide and lanreotide have limited ability to control the hypoglycemic events. Pasireotide is a multi-receptor targeted somatostatin-analog with improved affinity for SSTR5. There is to date no reported treatment experience with this drug in such tumors.

Case Description: A 72-year-old patient with a G2 stage IV insulinoma, who underwent excision of the primary pancreatic tumor and multiple hepatic metastases, required further treatment for recurrent hypoglycemic events. The glycemic control achieved with pasireotide LAR was better compared with lanreotide and everolimus. However, none of these treatments showed tumor anti-proliferative effects.

Conclusions: Pasireotide monthly injections achieved improved glycemic control in a patient with malignant insulinoma and recurrent hypoglycemic events compared with other medical treatments.

Citing Articles

Managing Hypoglycaemia in Patients With Insulinoma-A Tertiary Centre Experience and Review of the Literature.

Howarth S, Ho T, Wimbury J, Casey R Clin Endocrinol (Oxf). 2024; 102(3):344-354.

PMID: 39740208 PMC: 11788970. DOI: 10.1111/cen.15188.

Structural insights into somatostatin receptor 5 bound with cyclic peptides.

Li Y, Meng X, Yang X, Ling S, Shi P, Tian C Acta Pharmacol Sin. 2024; 45(11):2432-2440.

PMID: 38926478 PMC: 11489758. DOI: 10.1038/s41401-024-01314-8.

Pasireotide for Refractory Hypoglycemia in Malignant Insulinoma- Case Report and Review of the Literature.

Oziel-Taieb S, Maniry-Quellier J, Chanez B, Poizat F, Ewald J, Niccoli P Front Endocrinol (Lausanne). 2022; 13:860614.

PMID: 35518928 PMC: 9063459. DOI: 10.3389/fendo.2022.860614.

Pasireotide use for the treatment of endogenous hyperinsulinemic hypoglycemia refractory to conventional medical therapy: A case report and review of the literature.

Husni H, Khan S, Alghaieb B, Abusamaan M, Donner T, Hamrahian A Clin Case Rep. 2022; 10(3):e05650.

PMID: 35356161 PMC: 8940600. DOI: 10.1002/ccr3.5650.

Carcinoid Syndrome and Hyperinsulinemic Hypoglycemia Associated with Neuroendocrine Neoplasms: A Critical Review on Clinical and Pharmacological Management.

Spada F, Rossi R, Kara E, Laffi A, Massironi S, Rubino M Pharmaceuticals (Basel). 2021; 14(6).

PMID: 34199977 PMC: 8228616. DOI: 10.3390/ph14060539.